IMIPENEM

Imipenem is a broad-spectrum beta-lactam antibiotic belonging to the carbapenem class, used to treat multi-drug-resistant bacterial infections. The FDA approved imipenem in 1985. Clinical trials demonstrated efficacy against both Gram-positive and Gram-negative bacteria, including resistant strains such as Pseudomonas aeruginosa and Enterobacteriaceae. Its activity against these difficult-to-treat pathogens has established it as a significant option for managing complex infections, particularly in hospital and intensive care unit settings.

Imipenem is prescribed to treat a wide range of serious bacterial infections, including: Lower respiratory tract infections : Effective in treating bacterial pneumonia and other severe lung infections. Intra-abdominal infections : Used to manage infections in the abdomen, often caused by Gram-negative bacteria. Urinary tract infections (UTIs) : Treats complicated UTIs, particularly in patients with multi-drug resistant pathogens. Skin and soft tissue infections : Addresses infections resulting from resistant bacteria, commonly seen in hospital settings. Gynaecological infections : Effective in treating infections of the female reproductive organs.

Imipenem is available for intravenous administration, often combined with Cilastatin, a compound that prevents the antibiotic from being broken down in the kidneys, allowing higher concentrations in the bloodstream. The dosage varies based on infection severity and patient factors, generally ranging from 250 mg to 1 g every 6-8 hours. A healthcare professional should determine the precise dose and frequency.

Common side effects of Imipenem include: Nausea and vomiting Diarrhea Skin rash Injection site reactions Dizziness More severe side effects, though rare, include seizures, confusion, severe allergic reactions, and Clostridioides difficile-associated diarrhoea.

Seizure Risk : Imipenem may raise the likelihood of seizures, particularly in individuals with a history of central nervous system (CNS) disorders or those receiving high doses. Hypersensitivity Reactions : Like other beta-lactam antibiotics, Imipenem can cause allergic reactions, including anaphylaxis, particularly in individuals with penicillin allergies. Renal Impairment : Adjustments in dosage may be required for patients with kidney dysfunction, as the drug is primarily eliminated by the kidneys.

Avoid using Imipenem in patients with known allergies to carbapenems or beta-lactams. Extra caution is recommended for elderly patients, as they may be more prone to side effects, including CNS-related reactions. Monitor kidney function regularly, as Imipenem is excreted by the kidneys and may accumulate in cases of impaired renal function. Ensure proper hydration during treatment to minimise the risk of renal complications.

Completion of the entire prescribed course of Imipenem is necessary to prevent resistance development and ensure adequate treatment response. Patients who experience unusual symptoms including severe headache, confusion, or rash should seek medical attention, as these may indicate an adverse reaction. Adequate hydration supports kidney function and reduces the risk of renal adverse effects. Patients receiving Imipenem, particularly those with renal impairment or a history of seizures, require regular monitoring of kidney function and central nervous system status.

https://pubchem.ncbi.nlm.nih.gov/compound/Imipenem#section=NIPH-Clinical-Trials-Search-of-Japan https://go.drugbank.com/drugs/DB01598 https://www.sciencedirect.com/topics/medicine-and-dentistry/imipenem